ENSEM Therapeutics, a CBC Group Incubated Biopharmaceutical Company, Raises $67M in Series A Funding to Develop Small Molecule Drugs for Hard-to-Treat Targets
BOSTON, April 6, 2022 /PRNewswire/ — ENSEM Therapeutics Inc. (ENSEM), a Bostonbiotech company specializing in high-value, difficult-to-treat oncology targets, today announced the closing of a Series A2 financing. Incubated by CBC Group since 2021, the funding is led by GGV Capital, with participation from Pavilion Capital, Cenova Capital, Mitsui & Co. Global Investment, Inc. and CBC Group, bringing the Series A total to $67 million.
“The pharmaceutical/biotech industry has faced a severe bottleneck imposed by a limited number of drug targets and the slowness with which new discoveries can be advanced to clinical trials.” noted Sean Cao, CEO of ENSEM and Managing Director of the CBC Group. “The ENSEM team is made up of seasoned drug hunters with extensive experience in advancing new drugs through clinical trials and regulatory approvals. We will combine new tools coupled with AI and learning automatic to break down these barriers.”
“Biomolecules such as proteins and RNAs are in constant motion, with a set of conformations that govern their functions. Traditional approaches have been ineffective in productively capturing these dynamic states due to experimental and computational limitations,” said Shengfang Jin, Ph.D., President and Scientific Director of ENSEM. “Our team developed Kinetic EnsembleMT, a new multi-level platform integrating molecular simulation, AI deep learning and advanced experimental validation by state-of-the-art macromolecular dynamic techniques. We expect many of these programs to reveal non-obvious binding sites as drug targets and create new classes of small molecule therapeutics. »
“ENSEM has made remarkable progress in a short time,” said Joshua Wu, Partner of GGV Capital. “The rich industrial and technical expertise of this founding team and its unique platform are the main strengths of an exciting AI drug discovery venture. We believe that ENSEM’s differentiated technologies will enable a new generation of drug targets. We are delighted to co-lead the A2 Funding series and partner with the ENSEM team to accelerate its growth.”
Profits will be used to advance the company’s Kinetic SetMT platform and accelerate the R&D pipeline.
About ENSEM Thérapeutique
ENSEM is a pioneering drug discovery and development company that relies on its unique kinetic packageMT platform to develop innovative small molecule precision drugs for oncology, with potential expansion into genetic disorders and other disease areas. ENSEM integrates computational deep learning and AI methodologies with advanced experimental techniques to identify non-obvious binding pockets and accelerate structure-based drug design, with a focus on large targets. valuable and difficult to deal with.
For more information, please visit www.ensemtx.com.
About the Radio-Canada Group
Radio Canada Group, from Asia investment company dedicated to health, is committed to creating value and integrating global resources. Partnering with the world’s top entrepreneurs and scientists, its unique investor-operator approach has enabled leading global healthcare companies to expand access to affordable medical care, catalyze innovation and improve health. effectiveness in meeting unmet medical needs worldwide. Founded in 2014, CBC has a leading team of investment, industry and portfolio management professionals headquartered in Singapore with offices at Shanghai, beijing, hong kong and new Yorkand presences in Boston, San Diego, San Franciscoand Tokyo. CBC is focused on platform building, buyout, credit and growth-driven opportunities in several key areas of the healthcare industry, including pharmaceuticals and biotechnology, medical technology and healthcare services.
For more information, please visit www.cbridgecap.com.
About GGV
GGV Capital is a global venture capital firm that invests in local founders. With $9.2 billion under our leadership, we have investments in United States, Canada, China, South East Asia, India, Latin Americaand Israel. As a multi-stage, industry-focused company, GGV Capital invests in growth-stage companies in three sectors: Social/Internet, Enterprise Tech and Smart Tech. Over the past two decades, we have supported more than 400 companies around the world, including Affirm, Airbnb, Alibaba, Big Commerce, Boss Zhipin, Grab, HashiCorp, Hello, JD MRO, Keep, Kujiale, Manbang, NIU, Opendoor Technologies, Peloton, Poshmark, Qunar/Ctrip, Slack, Square, StockX, Udaan, Wish, Xpeng, Zendesk, etc.
About Pavcap
Pavilion Capital International Pte. ltd. (Pavilion) is an investment company established in Singapore in 2012. Pavilion focuses on private equity/venture capital funds and direct investments in companies that benefit from economic growth and the transformation of North Asia and South East Asia. Pavilion is looking for investment opportunities in different sectors, especially in technology and healthcare.
Pavilion is an indirect wholly owned subsidiary of Temasek Holdings.
About Cenova
Cenova Capital is a leading healthcare fund dedicated to early stage and growth investing in the life sciences and healthcare sectors. Since its creation in 2010, Cenova Capital now has six funds under management with investments in more than 80 companies in the fields of pharmaceuticals, medical devices, health services and digital health.thath. Cenova Capital’s investors are primarily large international institutional investors, including Asian sovereign investors, insurance companies, financial institutions and multinational corporations.
About Mitsui & Co. Global Investment, Inc.
Mitsui & Co. Global Investment, Inc. (MGI), a wholly owned subsidiary of Mitsui & Co. Ltd., was established in 1996, with headquarters in Silicon Valley and branches in Tokyo and beijing. MGI is committed to investments in startups and focus areas spanning IT and communications, healthcare, biotechnology and industrial opportunities. Since its inception, MGI has invested in and managed over 100 portfolio companies. Our vision is to leverage Mitsui’s global network and provide portfolio companies with support to grow their business and guide them on the global stage.
contacts
E-MAIL
[email protected]
CALL
781-874-2500
SOURCE Radio-Canada Group
Comments are closed.